

ASX ANNOUNCEMENT

29th March 2022

RESPIRI APPOINTS EAS ADVISORS LLC AS US CORPORATE ADVISOR TO ASSIST WITH US GROWTH

Respiri Limited (ASX:RSH) (“**Respiri**” or the “**Company**”), an eHealth SaaS Company supporting respiratory health management is pleased to advise that it has executed a binding consulting agreement with EAS Advisors LLC (“**EAS**”).

EAS is a private, New York-based boutique corporate advisory firm providing a unique service to small and mid-cap companies. The foundation of EAS's business is built on industry knowledge, capital markets insights and access to a deep pool of traditional and alternative sources of capital. In addition to exposure to US investors, EAS provides companies with access to local industry contacts to enhance their growth and expansion. Founded in 2008, EAS provides a range of services to clients, including institutional market engagement, equity and debt raising and M&A and capital markets advisory. Since inception, EAS has participated in over US\$6.5 billion of successful transactions. EAS operates under the broker dealer license of Odeon Capital Group LLC - member of FINRA/SIPC/MSRB/NFA. More details on EAS Advisors can be found on EAS's website at <https://easadvisors.com/>.

Respiri launched its USA business in December 2021, nine months ahead of schedule, through carefully selected Remote Patient Monitoring (RPM) provider partners who have established relationships with payors, physicians, hospitals and Accountable Healthcare Organisations (ACOs). The company strategy is to continue to leverage the RPM CPT reimbursement codes that wheezo® qualifies for allowing physicians to provide wheezo® to their patients to monitor their respiratory conditions from the real world, in real time and be remunerated for providing these important healthcare services. These RPM respiratory services also appeal as it should also result in reduced exacerbations and hospitalisations which are a major health and financial burden to institutions, payors and society. The response wheezo® has received from payors and physicians has been particularly positive due to the simplicity of the solution and because it provides physicians with the first real RPM solution in respiratory medicine.

CEO and Managing Director of Respiri, Mr Marjan Mikel said “After seeing the impressive work EAS has done with other ASX listed companies in bringing them to a wider US audience we’re delighted to be working with the team at EAS as Respiri continues its growth in the US market.”

EAS Principal and Founder, Mr Edward Sugar said: “After reviewing the business plans Respiri has for the US market, we are confident in the opportunity and we’re looking forward to working with the experienced and knowledgeable management team at Respiri as they roll out their wheezo® product and technology into the US market.”

- ENDS -

For further information, investors and media please contact:

Mr Marjan Mikel
CEO & Managing Director
Respiri Limited
P: +61 408 462 873
E: marjan@respiri.co

Mr Nicholas Smedley
Executive Chairman
Respiri Limited
P: +61 447 074 160
E: nicholas@respiri.co

This ASX announcement dated 29th March 2022 has been authorised for release by the Board of Directors of Respiri Limited.

About Respiri Limited

Respiri is an e-Health SaaS company supporting respiratory health management. Its world-first technology detects wheeze, a typical symptom of asthma, COPD and respiratory disease to provide an objective measure of airway limitation. wheezo®, Respiri's innovative technology, comprises an eHealth app combined with a simple, easy to use, handheld device. wheezo® is the first smart device to help improve asthma management by monitoring wheeze and documenting symptoms, signs, triggers, weather conditions and medication use. The asthma management platform also facilitates the sharing of data with caregivers, physicians and other health care professionals.

Respiri's mission is to help improve quality of life for hundreds of millions of children and adults around the world and dramatically reduce hospital admissions and the economic burden of asthma. Respiri Limited's operations are based in Melbourne, Australia.

For additional information about Respiri and its products, please visit www.respiri.co

About wheezo®

Developed in Australia, with the support of respiratory specialists and other healthcare professionals, the innovative wheezo® device analyses breath sounds for wheeze, and the eHealth App assists patients with managing their asthma by tracking symptoms, triggers, medication use and geo-specific weather conditions. The platform has been designed to extend asthma management beyond the clinic and make it easy to share information with doctors and make appropriate adjustments to asthma action plans. Better active management may lead to better outcomes and improved quality of life for the asthma patient.

For further information about wheezo®, follow the online link <https://wheezo.com>
wheezo® is a registered trademark of Respiri Limited.

Forward Looking Statements

Certain statements made in this announcement are forward-looking statements. These forward looking statements are not historical facts but rather are based on Respiri current expectations, estimates and projections about the industry in which Respiri operates, and its beliefs and assumptions. Words such as "anticipates," "expects," "intends," "plans," "believes," "seeks," "estimates," "guidance" and similar expressions are intended to identify forward looking statements and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties, particularly those risks or uncertainties inherent in the process of developing technology and in the endeavour of building a business around such products and services. These statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and other factors, some of which are beyond the control of Respiri, are difficult to predict and could cause actual results to differ materially from those expressed or forecasted in the forward looking statements. Respiri cautions shareholders and prospective shareholders not to place undue reliance on these forward looking statements, which reflect the view of Respiri only as of the date of this release. The forward looking statements made in this announcement relate only to events as of the date on which the statements are made. Respiri will not undertake any obligation to release publicly any revisions or updates to these forward looking statements to reflect events, circumstances or unanticipated events occurring after the date of this announcement except as required by law or by any appropriate regulatory authority.